Crescent Biopharma
CBIO
76 hedge funds and large institutions have $90.4M invested in Crescent Biopharma in 2020 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 30 increasing their positions, 25 reducing their positions, and 12 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 25
0.05% less ownership
Funds ownership: 0.96% → 0.91% (-0.05%)
3% less funds holding
Funds holding: 78 → 76 (-2)
17% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 12
59% less capital invested
Capital invested by funds: $220M → $90.4M (-$129M)
86% less call options, than puts
Call options by funds: $2K | Put options by funds: $14K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$4.3M |
| 2 |
Renaissance Technologies
New York
|
+$1.24M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$1.17M |
| 4 |
Morgan Stanley
New York
|
+$790K |
| 5 |
Walleye Capital
New York
|
+$649K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$9.11M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
-$4.17M |
| 3 |
Axa
Paris,
France
|
-$3.5M |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$704K |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$577K |
CBIO Hedge Fund Activity: Q1 2020 in Review
76 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Crescent Biopharma (CBIO) for Q1 2020, worth a combined $90.4M — down 59% from $220M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of CBIO and 10 opened new positions — a net loss of 2 holders — while 25 trimmed existing stakes and 30 added.
The largest buyer was Wellington Management Group, adding an estimated $4.3M. The largest seller was Invesco, cutting an estimated $9.11M.
- 76 institutional investors held Crescent Biopharma (CBIO) as of Q1 2020, down from 78 in Q4 2019.
- Funds reported $90.4M of Crescent Biopharma stock for Q1 2020, down 59% quarter-over-quarter.
- 10 funds opened new Crescent Biopharma positions in Q1 2020 and 12 closed out, a net change of -2 holders.
- The largest Crescent Biopharma buyer in Q1 2020 was Wellington Management Group, an estimated $4.3M added.
- The largest Crescent Biopharma seller in Q1 2020 was Invesco, an estimated $9.11M sold.
Based on aggregated 13F filings for Q1 2020.